RxDoctor Payments Data

Jennifer Buczyner, MD

Neurology · Jupiter, FLNPI 1386841773

Payments from drug & device makers

$438,492in general payments, 2019–2025

Across 1,304 payments — averaging $336.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$153K
  • Lilly USA, LLC$69K
  • Amgen$58K
  • AbbVie$56K
  • Argenx US, Inc.$29K
  • Biohaven Pharmaceuticals, Inc.$20K
  • plus $53K from 54 others

What the payments were for

  • Consulting fees$29,2007%
  • Speaking & faculty fees$339,47582%
  • Travel & lodging$22,6935%
  • Food & beverage$24,0346%
  • Education$3570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)204$153,105
Lilly USA, LLC155$68,841
Amgen89$58,240
AbbVie(2 entities)166$55,697
Argenx US, Inc.50$29,206
Biohaven Pharmaceuticals, Inc.33$20,082
UCB, Inc.106$18,003
Eli Lilly30$17,479
Biohaven Pharmaceutical Holding Company Ltd.23$5,635
Eisai Inc.24$3,095
Corium, LLC7$1,303
Novartis105$1,274
Pfizer52$1,011
Biogen58$1,004
Teva Pharmaceuticals USA, Inc.38$811
Medtronic(2 entities)4$312
Supernus Pharmaceuticals, Inc.19$273
Merz Pharmaceuticals, LLC11$250
MDD US Operations, LLC11$211
EMD Serono, Inc.10$181
Stryker1$164
Octapharma USA, Inc.3$157
C2n Diagnostics, LLC6$155
Acorda Therapeutics, Inc7$148
Neurocrine Biosciences, Inc.2$136
Kyowa Kirin, Inc.5$121
Lundbeck LLC5$118
Otsuka America Pharmaceutical, Inc.6$113
Takeda Pharmaceuticals U.S.A., Inc.9$109
Idorsia Pharmaceuticals US Inc5$103
Tanabe Pharma America, Inc.3$69
Bayer3$64
Sumitomo Pharma America, Inc.3$62
Merck4$62
CSL Behring3$60
Genentech USA, Inc.2$58
Nevro Corp.2$55
Sanofi3$55
Avanir Pharmaceuticals, Inc.2$43
Alnylam Pharmaceuticals Inc.2$41
Boston Scientific2$36
Amneal Pharmaceuticals LLC2$35
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$34
Arbor Pharmaceuticals, Inc.2$34
Johnson & Johnson2$34
Bristol Myers Squibb2$33
Jazz Pharmaceuticals Inc.2$30
Sanofi Pasteur Inc.2$29
Amarin Pharma, Inc.2$24
SK Life Science, Inc.1$24
Abbott1$23
Almatica Pharma LLC1$22
TG Therapeutics, Inc.1$21
Impel Pharmaceuticals Inc.1$21
Catalyst Pharmaceuticals, Inc.1$21
Optinose US, Inc.1$20
Averitas Pharma Inc.1$20
Acadia Pharmaceuticals Inc1$20
Microtransponder, Inc.1$18
Portola Pharmaceuticals, LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$438,492 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$3,163,816
Medicare patients
1,361
Services billed
201,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone12$390,566
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5017$355,810
OctagamImmun Globg(Igg)/Malt/Iga Ov5016$296,762
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$195,182
ZeposiaOzanimod Hydrochloride12$99,787
RytaryCarbidopa/Levodopa50$74,261
Nurtec OdtRimegepant Sulfate26$42,087
Aimovig AutoinjectorErenumab-Aooe29$30,927
Trokendi XrTopiramate13$21,805
QuliptaAtogepant20$21,260
Ajovy AutoinjectorFremanezumab-Vfrm14$19,934
NeuproRotigotine15$17,634
Glatiramer Acetate12$16,599
Emgality PenGalcanezumab-Gnlm21$14,209
Dalfampridine ErDalfampridine12$13,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$1,004$390,56612 claims
PfizerOctagam, Nurtec Odt$1,011$338,84942 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$109$195,18211 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$35$75,58961 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$273$21,80513 claims
AbbVieQulipta$55,697$21,26020 claims
UCB, Inc.Neupro$18,003$17,63415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →